Tenax Therapeutics (TENX) Research & Development (2010 - 2026)
Tenax Therapeutics recorded quarterly Research & Development of $11.5 million in Q1 2026, up 9.48% quarter-over-quarter from $10.5 million in Q4 2025, and up 103.04% year-over-year from $5.7 million in Q1 2025.
Tenax Therapeutics' Research & Development history runs 16 years deep, the most recent figure standing at $11.5 million for Q1 2026.
- In Q1 2026, Research & Development rose 103.04% year-over-year to $11.5 million; the TTM figure through Mar 2026 stood at $38.5 million (up 145.15% YoY), while the FY2025 annual figure was $32.7 million, up 157.08% from the prior year.
- Research & Development came in at $11.5 million for Q1 2026 at Tenax Therapeutics, up from $10.5 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $11.5 million in Q1 2026 to a low of $197903.0 in Q2 2023.
- A 5-year average of $3.9 million and a median of $2.3 million in 2024 frame the typical range for Research & Development.
- Across the five-year window, Research & Development plunged 94.74% in 2022 and surged 1075.83% in 2024, its largest moves.
- Tenax Therapeutics' Research & Development stood at $1.1 million in 2022, then surged by 49.76% to $1.7 million in 2023, then jumped by 170.31% to $4.6 million in 2024, then surged by 129.43% to $10.5 million in 2025, then increased by 9.48% to $11.5 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $11.5 million, $10.5 million, and $10.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Tenax Therapeutics | 542.72 Mn | 542.72 Mn | - | 11.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.54 Mn |
| Dec 31, 2025 | 10.54 Mn |
| Sep 30, 2025 | 10.33 Mn |
| Jun 30, 2025 | 6.12 Mn |
| Mar 31, 2025 | 5.68 Mn |
| Dec 31, 2024 | 4.59 Mn |
| Sep 30, 2024 | 3.11 Mn |
| Jun 30, 2024 | 2.33 Mn |
| Mar 31, 2024 | 2.68 Mn |
| Dec 31, 2023 | 1.70 Mn |
| Sep 30, 2023 | 1.07 Mn |
| Jun 30, 2023 | 197,903.00 |
| Mar 31, 2023 | 265,735.00 |
| Dec 31, 2022 | 1.13 Mn |
| Sep 30, 2022 | 1.54 Mn |
| Jun 30, 2022 | 1.52 Mn |
| Mar 31, 2022 | 1.18 Mn |
| Dec 31, 2021 | 915,600.00 |
| Sep 30, 2021 | 1.16 Mn |
| Jun 30, 2021 | 693,222.00 |
| Mar 31, 2021 | 22.38 Mn |
| Dec 31, 2020 | 890,963.00 |
| Sep 30, 2020 | 1.05 Mn |
| Jun 30, 2020 | 1.27 Mn |
| Mar 31, 2020 | -1.34 Mn |
| Dec 31, 2019 | 5.52 Mn |
| Sep 30, 2019 | -916,984.00 |
| Jun 30, 2019 | -649,254.00 |
| Mar 31, 2019 | -482,767.00 |
| Dec 31, 2018 | 1.97 Mn |
| Sep 30, 2018 | -362,628.00 |
| Jun 30, 2018 | -311,151.00 |
| Mar 31, 2018 | -58,588.00 |
| Dec 31, 2017 | 7.06 Mn |
| Sep 30, 2017 | -253,973.00 |
| Jun 30, 2017 | -1.22 Mn |
| Mar 31, 2017 | -2.05 Mn |
| Dec 31, 2016 | 23.75 Mn |
| Sep 30, 2016 | -3.23 Mn |
| Jun 30, 2016 | -3.43 Mn |
| Mar 31, 2016 | 3.94 Mn |
| Dec 31, 2015 | 6.48 Mn |
| Sep 30, 2015 | 1.68 Mn |
| Jun 30, 2015 | 1.95 Mn |
| Apr 30, 2013 | 844,523.00 |
| Jan 31, 2013 | 369,447.00 |
| Oct 31, 2012 | 604,574.00 |
| Jul 31, 2012 | 637,272.00 |
| Apr 30, 2012 | 722,165.00 |
| Jan 31, 2012 | 599,935.00 |
| Oct 31, 2011 | 488,577.00 |
| Jul 31, 2011 | 651,961.00 |
| Apr 30, 2011 | 465,300.00 |
| Jan 31, 2011 | 498,521.00 |
| Oct 31, 2010 | 572,649.00 |
| Jul 31, 2010 | 1.15 Mn |